

STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021



CIN - L51900MH1985PLC035738

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2015

PART I

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Nine Months ended		Twelve Months ended
		30-09-15	30-06-15	30-09-14	30-09-15	30-09-14	31-12-14
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a) Net Sales/Income from Operations	10,703.44	11,689.57	17,275.08	32,456.00	54,532.25	66,695.07
	b) Other Operating Income	98.92	118.69	100.52	360.14	292.89	368.20
	c) Total Income from Operations	10,802.36	11,808.26	17,375.60	32,816.14	54,825.14	67,063.27
2	Expenses						
	a) Cost of materials consumed	6,358.94	7,971.45	21,248.84	31,660.21	52,986.94	61,783.87
	b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	923.77	(347.48)	(8,790.05)	(9,972.34)	(15,279.28)	(15,232.62)
	d) Employee benefits expense	1,301.14	1,345.48	1,289.83	3,873.61	3,950.41	5,167.27
	e) Depreciation and amortization expense	7,020.70	7,017.02	6,382.47	21,087.27	19,177.09	27,657.43
	f) Other Expenses	731.75	702.51	850.91	2,316.25	2,920.59	3,852.80
	g) Total Expenses	16,336.30	16,688.98	20,982.00	48,965.00	63,755.75	83,228.75
3	Profit / (Loss) from Operations before Other Income and finance Costs (1-2)	(5,533.94)	(4,880.72)	(3,606.40)	(16,148.86)	(8,930.61)	(16,165.48)
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from Ordinary activities before finance costs (3+4)	(5,533.94)	(4,880.72)	(3,606.40)	(16,148.86)	(8,930.61)	(16,165.48)
6	Finance Costs	8,411.97	8,217.04	12,857.94	24,268.37	38,190.74	46,950.57
7	Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)	(13,945.91)	(13,097.76)	(16,464.34)	(40,417.23)	(47,121.35)	(63,116.05)
8	Tax expense						
	a) Current	0.00	0.00	0.00	0.00	0.00	0.00
	b) Deferred	(4,525.00)	(4,250.00)	(5,342.00)	(13,114.00)	(15,289.00)	(20,478.00)
	c) Total	(4,525.00)	(4,250.00)	(5,342.00)	(13,114.00)	(15,289.00)	(20,478.00)
9	Net Profit / (Loss) from Ordinary Activities after tax (7-8)	(9,420.91)	(8,847.76)	(11,122.34)	(27,303.23)	(31,832.35)	(42,638.05)
10	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit / (Loss) for the period (9+10)	(9,420.91)	(8,847.76)	(11,122.34)	(27,303.23)	(31,832.35)	(42,638.05)
12	Prior year adjustment	0.00	0.00	(550.00)	0.00	(1,200.00)	(3,132.47)
13	Profit available for appropriation	(9,420.91)	(8,847.76)	(11,672.34)	(27,303.23)	(33,032.35)	(45,770.52)
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,720.48	2,720.48	2,720.48	2,720.48	2,720.48	2,720.48
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						101,026.03
16.i	Earnings Per Equity Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)						
	a) Basic	(3.46)	(3.25)	(4.09)	(10.04)	(11.70)	(15.67)
	b) Diluted	(2.18)	(2.04)	(2.57)	(6.31)	(7.35)	(9.85)
16.ii	Earnings Per Equity Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)						
	a) Basic	(3.46)	(3.25)	(4.29)	(10.04)	(12.14)	(16.82)
	b) Diluted	(2.18)	(2.04)	(2.70)	(6.31)	(7.63)	(10.57)

STERLING BIOTECH LIMITED
 Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021
 CIN - L51900MH1985PLC035738
 Select Information for the Quarter ended 30 September 2015

PART II

Sr. No.	Particulars	Three Months ended			Nine Months ended		Twelve Months ended
		30-09-15	30-06-15	30-09-14	30-09-15	30-09-14	31-12-14
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Equity shares	135,545,090	135,545,090	135,545,090	135,545,090	135,545,090	135,545,090
	- Percentage of shareholding	49.82%	49.82%	49.82%	49.82%	49.82%	49.82%
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of Equity shares	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835
	Percentage of Shares (as a % of the total Equity shareholding of promoter and promoter group)	55.94%	55.94%	55.94%	55.94%	55.94%	55.94%
	Percentage of shares (as a % of the total Equity share capital of the Company)	18.68%	18.68%	18.68%	18.68%	18.68%	18.68%
	b) Non-encumbered						
	Number of Equity shares	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300
	Percentage of Shares (as a % of the total Equity shareholding of promoter and promoter group)	44.06%	44.06%	44.06%	44.06%	44.06%	44.06%
	Percentage of shares (as a % of the total Equity share capital of the Company)	14.71%	14.71%	14.71%	14.71%	14.71%	14.71%

Sr. No.	Particulars	Quarter ended 30/09/2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the Quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 6 November 2015.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30 September 2015
- 4 The Company has Overseas Subsidiaries and there are no business operations in the subsidiary companies.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary.

Place : Mumbai
 Date : 6 November 2015.



For and on Behalf of
 STERLING BIOTECH LIMITED

(Signature)
 Chetan J. Sandesara
 Joint Managing Director
 DIN - 00255671



H. S. HATHI & CO.

Chartered Accountants

110/5, Gajanan Building,
Jawahar Nagar, Goregaon (W),
Mumbai – 400 062.

✉ - hshathicompany@gmail.com

☎ - 022-2873 0828

CA. HEMANT S. HATHI
B.Com., LLB., FCA

Review Report to Board of Directors of Sterling Biotech Limited

43, Atlanta,
Nariman Point,
Mumbai – 400 021.

I have reviewed the accompanying statement of unaudited financial results of **Sterling Biotech Limited** for the period ended 30th September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by me. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. My responsibility is to issue a report on these financial statements based on my review.

I conducted my review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. I have not performed an audit and accordingly, I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For H. S. Hathi & Co.
Chartered Accountants
Firm Reg. No. : **103596W**

Hemant S. Hathi
Membership No. 37109
Proprietor

Place : Mumbai
Date : 06-11-2015